Stockscreener 앱 받기
1.27
9.48%
0.11
시간 외 거래:
1.28
0.01
+0.79%
전일 마감가:
$1.16
열려 있는:
$1.15
하루 거래량:
670.76K
Relative Volume:
2.67
시가총액:
$86.70M
수익:
$8.23M
순이익/손실:
$-32.49M
주가수익비율:
-2.1525
EPS:
-0.59
순현금흐름:
$-19.91M
1주 성능:
+5.83%
1개월 성능:
+25.74%
6개월 성능:
-16.99%
1년 성능:
+45.99%
1일 변동 폭
$1.15
$1.31
1주일 범위
$1.09
$1.31
52주 변동 폭
$0.6501
$2.12
Clearside Biomedical Inc Stock (CLSD) Company Profile
명칭
Clearside Biomedical Inc
전화
678-270-3631
주소
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-15 | 재개 | Wedbush | Outperform |
| 2021-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-05-13 | 개시 | ROTH Capital | Buy |
| 2019-08-09 | 다운그레이드 | Needham | Buy → Hold |
| 2018-11-05 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2018-11-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2018-11-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-06 | 재확인 | Needham | Buy |
| 2017-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2017-02-24 | 개시 | JP Morgan | Overweight |
| 2016-11-10 | 재확인 | Needham | Buy |
| 2016-10-24 | 재확인 | Stifel | Buy |
모두보기
Clearside Biomedical Inc 주식(CLSD)의 최신 뉴스
Wall Street SWOT: Clearside Biomedical stock eyes ODYSSEY trial success - Investing.com
Armistice Capital LLC Has $2.78 Million Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD) - MarketBeat
CLSD’s Stock Market Journey: A Year of Growth, Decline, and Uncertainty - The InvestChronicle
Financial Health Report: Clearside Biomedical Inc (CLSD)’s Ratios Tell a Tale - The Dwinnex
Can Clearside's ODYSSEY Trial Data Delight Investors? - RTTNews
CLSD’s Stock Market Adventure: 5.13% YTD Growth Amidst Volatility - The InvestChronicle
Nothing is Better Than Clearside Biomedical Inc (CLSD) stock at the moment - SETE News
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Large Increase in Short Interest - MarketBeat
Clearside Biomedical Inc [CLSD] Shares Rise 3.05 % on Thursday - Knox Daily
Was anything positive for Clearside Biomedical Inc (CLSD) stock last session? - US Post News
Clearside Biomedical Inc (CLSD) Stock: Navigating a Year of Volatility - The InvestChronicle
The Attractiveness of Investing In Clearside Biomedical Inc (CLSD) is Growing - Knox Daily
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Rating of "Buy" from Brokerages - MarketBeat
International Assets Investment Management LLC Has $26,000 Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Share Price Crosses Below Fifty Day Moving Average of $1.12 - MarketBeat
Market Resilience: Clearside Biomedical Inc (CLSD) Finishes Weak at 0.93, Down -3.40 - The Dwinnex
Analysts review Clearside Biomedical Inc’s rating - Knox Daily
Clearside Slips on Trials - MSN
Clearside Biomedical Inc [CLSD] Investment Guide: What You Need to Know - Knox Daily
Quarterly Metrics: Quick and Current Ratios for Clearside Biomedical Inc (CLSD) - The Dwinnex
Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at HC Wainwright - Defense World
Clearside Biomedical (NASDAQ:CLSD) Receives Buy Rating from HC Wainwright - MarketBeat
Jones Trading maintains stock target, buy rating on Clearside Biomedical By Investing.com - Investing.com Canada
Jones Trading maintains stock target, buy rating on Clearside Biomedical By Investing.com - Investing.com UK
Clearside Slips on Trials - Baystreet.ca
Clearside Biomedical Announces Completion of Final - GlobeNewswire
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD - StockTitan
Assenagon Asset Management S.A. Buys Shares of 283,193 Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Brokers Issue Forecasts for Clearside Biomedical, Inc.'s FY2024 Earnings (NASDAQ:CLSD) - MarketBeat
Brokers Issue Forecasts for Clearside Biomedical, Inc.’s FY2024 Earnings (NASDAQ:CLSD) - Defense World
Assenagon Asset Management S.A. Takes $368,000 Position in Clearside Biomedical, Inc. (NASDAQ:CLSD) - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Earns Buy Rating from Analysts at Chardan Capital - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Research Coverage Started at Chardan Capital - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Shares Bought by Vanguard Group Inc. - Defense World
Clearside Biomedical (CLSD) Stock Price, News & Analysis - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) to Post Q3 2024 Earnings of ($0.13) Per Share, HC Wainwright Forecasts - Defense World
Q3 2024 EPS Estimates for Clearside Biomedical, Inc. (NASDAQ:CLSD) Increased by Analyst - MarketBeat
Oppenheimer gives an Outperform recommendation for Clearside Biomedical Inc (CLSD) - Knox Daily
Clearside Biomedical (NASDAQ:CLSD) Receives “Buy” Rating from HC Wainwright - Defense World
Clearside Biomedical (NASDAQ:CLSD) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Up 76.8% in July - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Up 76.8% in July - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $4.60 Consensus Price Target from Analysts - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Clearside Biomedical (NASDAQ:CLSD) Earns Buy Rating from Needham & Company LLC - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at Needham & Company LLC - Defense World
CLSD Stock Earnings: Clearside Biomedical Beats EPS, Misses Revenue for Q2 2024 - InvestorPlace
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update - wallstreet:online
Clearside Biomedical Inc (CLSD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):